Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; 10 of the 10 references it cites were found in a registry or an index.

Firing up the cold tumors by targeting Vps34

Open access

Abstract

Cancer immunotherapy based on anti-PD-1/PD-L1 blockade is particularly effective in responding to patients with hot tumors. These tumors are characterized by the accumulation of proinflammatory cytokines and T cell infiltration. In our recent report published in Science Advances, we demonstrate that targeting the autophagy-related protein Vps34 switched cold immune desert tumors into hot inflamed immune-infiltrated tumors and enhanced the efficacy of anti-PD-1/PD-L1. Our study provides the preclinical rationale to set up combination immunotherapy clinical trials using selective Vps34 inhibitors and immune checkpoint blockers in melanoma and CRC.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1080/2162402x.2020.1809936

Cites

10 of 10 references verified0 citation errors · 0 not checkable

Statistics

Figures

Figure 1. Vps34 inhibition improves anti-PD-1/PD-L1 immunotherapy by switching cold into hot tumors. Cold tumors are characterized by the absence of immune cells or the limited number of cytotoxic immune cells in the tumor microenvironment. Therefore, cold tumors are not eligible or most likely not responding to immunotherapy (1). Treatment of cold tumors with Vps34 inhibitors (2) induces the release by tumor cells of proinflammatory chemokines such as CCL5 and CXCL10. These chemokines drives more NK and CD8 T cells to the tumor microenvironment. Vps34i-treated tumors become hot and therefore eligible to anti-PD-1/PD-L1 based immunotherapy (3). Combined Vps34i with anti-PD-1/PD-L1 (4) improves the therapeutic benefit of immunotherapy and significantly decreases the tumor growth.5
Figure 1. Vps34 inhibition improves anti-PD-1/PD-L1 immunotherapy by switching cold into hot tumors. Cold tumors are characterized by the absence of immune cells or the limited number of cytotoxic immune cells in the tumor microenvironment. Therefore, cold tumors are not eligible or most likely not responding to immunotherapy (1). Treatment of cold tumors with Vps34 inhibitors (2) induces the release by tumor cells of proinflammatory chemokines such as CCL5 and CXCL10. These chemokines drives more NK and CD8 T cells to the tumor microenvironment. Vps34i-treated tumors become hot and therefore eligible to anti-PD-1/PD-L1 based immunotherapy (3). Combined Vps34i with anti-PD-1/PD-L1 (4) improves the therapeutic benefit of immunotherapy and significantly decreases the tumor growth.5CC BY-NC · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

  • PD-1 blockade induces responses by inhibiting adaptive immune resistance

    Tumeh, P. C., Harview, C. L., Yearley, J. H., Shintaku, I. P., Taylor, E. J. M., Robert, L., Chmielowski, B., Spasic, M., Henry, G., Ciobanu, V., et al. (2014) · Nature · doi:10.1038/nature13954 · Cited by 6,609 · cited 3×

    “Therefore, many ongoing clinical trials in immuno-oncology are focusing on strategies making cold tumors hot, so patients can better benefit from ICB.2 We have previously reported that hypoxia-induced autophagy in tumor cells was associated with tumor resistance to cytotoxic T lymphocyte-3 and natural killer cells (NK…”
    BackgroundInfluential
  • Chemokine expression in melanoma metastases associated with CD8+ T-cell recruitment

    Harlin, H., Meng, Y., Peterson, A. C., Zha, Y., Tretiakova, M., Slingluff, C., McKee, M., & Gajewski, T. F. (2009) · Cancer Research · doi:10.1158/0008-5472.can-08-2281 · Cited by 1,121 · cited 1×

    “We next evaluated the expression of several proinflammatory chemokines/cytokines involved in the recruitment of CD8 T cells into human melanomas.(10) Our data indicated that Vps34 inhibition induced the secretion of proinflammatory CCL5, CXCL10, and IFNγ within the tumor microenvironment, most likely generated by mela…”
    Background
  • Combination cancer immunotherapies tailored to the tumour microenvironment

    Smyth, M. J., Ngiow, S. F., Ribas, A., & Teng, M. W. L. (2016) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2015.209 · Cited by 944 · cited 1×

    “Despite the exciting and encouraging clinical responses obtained, the majority of patients treated with anti-CTLA-4, anti-PD-1, or anti-PD-L1 monotherapy still show none or partial objective responses.(1) Therefore, to achieve durable tumor regression in melanoma and CRC patients, there is a strong need to design new…”
    Background
  • Autophagy maintains tumour growth through circulating arginine

    Poillet-Perez, L., Xie, X., Zhan, L., Yang, Y., Sharp, D. W., Hu, Z. S., Su, X., Maganti, A., Jiang, C., Lu, W., et al. (2018) · Nature · doi:10.1038/s41586-018-0697-7 · Cited by 360 · cited 1×

    “However, the effect of targeting autophagy on the tumor immune landscape and its impact on the therapeutic benefit of ICB is still poorly explored.(6,7) Vacuolar protein sorting 34 (Vps34), also known as class III phosphoinositide 3-kinase (PIK3C3) is involved in the initiation of autophagy and in the process of endoc…”
    Background
  • Autophagy sustains pancreatic cancer growth through both cell-autonomous and nonautonomous mechanisms

    Yang, A., Herter-Sprie, G., Zhang, H., Lin, E. Y., Biancur, D., Wang, X., Deng, J., Hai, J., Yang, S., Wong, K.-K., et al. (2018) · Cancer Discovery · doi:10.1158/2159-8290.cd-17-0952 · Cited by 349 · cited 1×

    “However, the effect of targeting autophagy on the tumor immune landscape and its impact on the therapeutic benefit of ICB is still poorly explored.(6,7) Vacuolar protein sorting 34 (Vps34), also known as class III phosphoinositide 3-kinase (PIK3C3) is involved in the initiation of autophagy and in the process of endoc…”
    Background
  • Granzyme B degradation by autophagy decreases tumor cell susceptibility to natural killer-mediated lysis under hypoxia

    Baginska, J., Viry, E., Berchem, G., Poli, A., Noman, M. Z., van Moer, K., Medves, S., Zimmer, J., Oudin, A., Niclou, S. P., et al. (2013) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1304790110 · Cited by 344 · cited 1×

    “We have previously reported that hypoxia-induced autophagy in tumor cells was associated with tumor resistance to cytotoxic T lymphocyte-(3) and natural killer cells (NK)mediated killing.(4) Additionally, we showed that targeting autophagy improved the efficacy of cancer vaccination and promoted tumor regression in me…”
    BackgroundSelf-citation
  • Blocking Hypoxia-Induced Autophagy in Tumors Restores Cytotoxic T-Cell Activity and Promotes Regression

    Noman, M. Z., Janji, B., Kaminska, B., Van Moer, K., Pierson, S., Przanowski, P., Buart, S., Berchem, G., Romero, P., Mami-Chouaib, F., et al. (2011) · Cancer Research · doi:10.1158/0008-5472.can-11-1094 · Cited by 256 · cited 1×

    “Additionally, we showed that targeting autophagy improved the efficacy of cancer vaccination and promoted tumor regression in melanoma.(3) We further revealed that silencing the autophagy-related protein Beclin1 decreased tumor growth by inducing a massive infiltration of NK cells through the release of CCL5/RANTES by…”
    BackgroundSelf-citation
  • Inhibition of Vps34 reprograms cold into hot inflamed tumors and improves anti–PD-1/PD-L1 immunotherapy

    Noman, M. Z., Parpal, S., Van Moer, K., Xiao, M., Yu, Y., Arakelian, T., Viklund, J., De Milito, A., Hasmim, M., Andersson, M., et al. (2020) · Science Advances · doi:10.1126/sciadv.aax7881 · Cited by 255 · cited 2×

    “By using immunocompromised NOD SCID Gamma (NSG) mice or immunocompetent mice depleted for NK or CD8 cells, we demonstrated that both NK and CD8 T effector cells are the major immune cells controlling the growth of Vps34-targeted B16-F10 tumors.(9) We next evaluated the expression of several proinflammatory chemokines/…”
    BackgroundMethodSelf-citation
  • Targeting autophagy inhibits melanoma growth by enhancing NK cells infiltration in a CCL5-dependent manner

    Mgrditchian, T., Arakelian, T., Paggetti, J., Noman, M. Z., Viry, E., Moussay, E., Van Moer, K., Kreis, S., Guerin, C., Buart, S., et al. (2017) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1703921114 · Cited by 226 · cited 1×

    “We further revealed that silencing the autophagy-related protein Beclin1 decreased tumor growth by inducing a massive infiltration of NK cells through the release of CCL5/RANTES by melanoma cells.(5) However, the effect of targeting autophagy on the tumor immune landscape and its impact on the therapeutic benefit of I…”
    BackgroundSelf-citation
  • Ironing out VPS34 inhibition

    Marsh, T., & Debnath, J. (2014) · Nature Cell Biology · doi:10.1038/ncb3089 · Cited by 35

Show all 10 references

Cited by

See all 30

Metadata

Authors
Janji, B., Hasmim, M., Parpal, S., Berchem, G., & Noman, M. Z.
Affiliations
  • Luxembourg Institute of Health (LU)
  • Karolinska Institutet (SE)
  • Centre Hospitalier de Luxembourg (LU)
Corresponding author
Janji, Bassam
Venue
OncoImmunology
Published
2020-01
Volume
9
Issue
1
Pages
1809936-1809936
ISSN
  • 2162-4011 (ISSN-L)
  • 2162-402X
OpenAlex
W3081656916
Cited by
30
References
10
Citations by year
2025: 2 · 2024: 2 · 2023: 8 · 2022: 10 · 2021: 7 · 2020: 1
FWCI
2.35
Type
journal article
Language
en
Open access
Locations
  • OncoImmunology (publishedVersion, cc-by-nc)
  • PubMed Central (publishedVersion, cc-by-nc)
  • PubMed (publishedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion)
Funders
  • Luxembourg National Research (C18/BM/12670304/COMBATIC)
  • Fondation Cancer Luxembourg (FC/2018/06)
  • Kriibskrank Kanner Foundation (2016-08-15)
  • Janssen Cilag Pharma
  • Roche pharma
  • Action LIONS Vaincre le Cancer Luxembourg
Topics
  • Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Cell Biology › Autophagy in Disease and Therapy
  • Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
Keywords
Vps34, cold tumors, autophagy, immune checkpoint inhibitors, combination immunotherapy, tumor immune microenvironment, T cell infiltration, melanoma, colorectal cancer
MeSH terms
Autophagy-Related Proteins, Humans, Immunologic Factors, Immunotherapy, Melanoma

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Firing up the cold tumors by targeting Vps34. https://app.cochat.ai/papers/10.1080/2162402x.2020.1809936
The paper
Janji, B., Hasmim, M., Parpal, S., Berchem, G., & Noman, M. Z. (2020). Firing up the cold tumors by targeting Vps34. OncoImmunology. https://doi.org/10.1080/2162402x.2020.1809936

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.